Glioblastoma IDH Wildtype 9440/3
Giant cell glioblastoma 9441/3
Epithelioid glioblastoma 9440/3
Glioblastoma IDH Mutant 9440/3
The understanding of molecular subtypes of gliomas recently led to the World Health Organization Classification of Tumors of the Central Nervous System 2016 classification criteria for these tumors, introducing the concept of primary glioblastoma and secondary glioblastomas based on genetic alterations and gene or protein expression profiles.
With the advance of genomics research, there have been a new breakthrough in the molecular classification of gliomas. Glioblastoma (WHO grade Ⅳ) could be subtyped to proneural, neural, classical, and mesenchymal according to the mRNA expression. Low grade gliomas (WHO grade Ⅱ and Ⅲ) could be divided into 5 types using 1p/19q co-deletion, isocitrate dehydrogenase(IDH) mutation, and TERTp (promotor region) mutation. In 2016, a new classification of tumors of the central nervous system was proposed, and some new markers such as IDH1 mutation were introduced into the diagnosis of gliomas. Genotype and phenotype were integrated to diagnose gliomas. In the meantime, precision treatment for gliomas has also been vigorously developed 1).
see also primary glioblastoma.
see also secondary glioblastoma